Rabies Vaccine After Cat Bite And Scratch Injuries

As a trusted China manufacturer of human use rabies vaccines, AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. offers the Rabies Vaccine After Cat Bite And Scratch Injuries, a freeze-dried Vero cell rabies vaccine specifically indicated for post-exposure prophylaxis following cat-related injuries. Clinical data demonstrate a seroconversion rate reaching 100% within 14 days post-vaccination, with neutralizing antibody levels consistently exceeding the WHO protection threshold of 0.5 IU/ml, ensuring rapid and reliable immune protection.

Understanding the Risk

Many people hold the misconception that cat bites and scratches pose a lower rabies risk than dog bites. In reality, cats are also one of the primary hosts of the rabies virus, particularly stray cats and free‑roaming felines, which carry a significantly higher risk of virus transmission. According to WHO exposure classification, even minor scratches without bleeding fall under Category II, while any bleeding bite or mucous membrane contact with cat saliva is Category III – both require prompt medical attention and vaccination.

1. Category II Exposure: Includes scratches without bleeding, or nibbling of uncovered skin. This requires immediate wound cleaning and initiation of rabies vaccination.

2. Category III Exposure: Includes single or multiple transdermal bites or scratches with bleeding, or contact of cat saliva with mucous membranes. This requires both full‑course vaccination and infiltration injection of rabies immunoglobulin (20 IU/kg).

3. Fatal Consequence: Once clinical symptoms of rabies develop, the fatality rate is nearly 100%. Therefore, timely administration of the Rabies Vaccine is not merely a medical recommendation – it is a life‑saving necessity.

In summary, every cat‑related injury, regardless of severity, should be evaluated by a healthcare professional, and post‑exposure prophylaxis must be initiated without delay to eliminate the threat of rabies.

Product Overview

The Rabies Vaccine After Cat Bite And Scratch Injuries is a freeze‑dried Vero cell rabies vaccine for human use, manufactured by AIM Honor (Ningbo) Biopharmaceutical Co., Ltd., a leading China supplier with decades of experience in vaccine development. AIM Vaccine Co., Ltd. (Stock Code: 06660.HK) ranks as the second‑largest rabies vaccine manufacturer globally, covering the entire value chain from R&D and production to commercialization.

● Company Strength: The group owns four fully controlled licensed vaccine manufacturing companies, three vaccine research institutes, and four R&D centers, employing over 1,500 staff members. It is one of only two Chinese human vaccine companies equipped with P3 laboratory strategic resources.

● Product Portfolio: AIM offers two types of rabies vaccines for cat‑related injuries – a conventional Vero cell vaccine (using the indigenous aG strain) and a next‑generation serum‑free Vero cell vaccine (using the PV‑2061 strain). Both are specifically designed for post‑exposure prophylaxis after cat bites and scratches.

● Market Presence: These products have been supplied continuously to more than 2,000 CDC institutions and medical facilities across all 31 provinces in China, and are also exported to South America, Central Asia, South Asia, Africa, and other regions, contributing to global rabies prevention.

In essence, choosing AIM’s vaccine means partnering with a manufacturer that combines scientific excellence, production scale, and a proven track record in both domestic and international markets.

Core Principles of Prevention

Effective rabies prevention after cat bites and scratches relies on three interconnected principles. Each step must be executed correctly and promptly to ensure the best possible outcome.

1. Immediate and Thorough Wound Management: Rinse the wound with soapy water or clean running water for at least 15 minutes, then disinfect with iodophor or alcohol. This mechanical washing can significantly reduce the viral load and bacterial contamination at the injury site.

2. Timely Vaccination Initiation: For Category II exposure, start the vaccination series as soon as possible – ideally within 24 hours. For Category III, combine with rabies immunoglobulin (20 IU/kg) infiltrated around the wound to provide passive immunity while the vaccine stimulates active antibody production.

3. Strict Adherence to the Full Course: Complete the entire vaccination schedule without interruption. Whether using the 5‑dose regimen (days 0, 3, 7, 14, 28) or the WHO‑simplified 4‑dose schedule, every dose is essential to achieve and sustain protective antibody levels above 0.5 IU/ml.

In summary, these three pillars – wound care, timely vaccination, and full‑course compliance – form the gold standard for rabies prevention. The Rabies Vaccine is specifically formulated to fit seamlessly into this protocol, offering high immunogenicity and excellent tolerability.

Immunization Schedule and Efficacy

The Rabies Vaccine is available in two immunization schedules, both validated through rigorous clinical trials and real‑world use. The choice depends on patient preference and healthcare provider recommendations.

1. Standard 5‑Dose Regimen: Administered intramuscularly in the deltoid muscle (or anterolateral thigh for infants) on days 0, 3, 7, 14, and 28. This schedule has been widely used for decades and is recognized by WHO and national health authorities.

2. WHO‑Simplified 4‑Dose Regimen: Supported by the serum‑free vaccine, this schedule reduces the number of visits to four doses (days 0, 3, 7, and 28) while maintaining equivalent immunogenicity. It improves patient compliance, especially for those who may have difficulty returning for multiple injections.

3. Proven Immunogenicity: Both vaccines achieve a seroconversion rate of 100% by day 14. Neutralizing antibody titers reach levels far above the 0.5 IU/ml protective threshold, often exceeding 10 IU/ml, ensuring robust and lasting immunity against rabies virus.

In practice, both schedules are equally effective when administered correctly. The vaccine’s high potency and consistent batch‑to‑batch quality guarantee that every dose delivers the expected immune response, giving patients and healthcare providers complete confidence in post‑exposure protection.

Safety and Quality Assurance

Safety is paramount for any vaccine intended for post‑exposure use. The Rabies Vaccine  undergoes stringent quality control at every production stage, meeting both Chinese national standards and WHO international guidelines.

● Preservative‑Free Formulation: The conventional vaccine contains no added preservatives, minimizing the risk of local irritation or allergic reactions. Residual bovine serum albumin is kept at ≤10 ng per dose, far below the industry limit.

● Serum‑Free Technology: The serum‑free vaccine is produced entirely without bovine serum, eliminating risks of serum‑related allergies and contamination. This makes it particularly suitable for children, the elderly, and individuals with allergic constitutions.

● Regulatory Approvals: The conventional vaccine holds National Drug Approval Number S20073014 and has maintained a 100% batch release qualification rate for 17 consecutive years. The serum‑free vaccine has completed Phase III clinical trials, and its marketing authorization application has been accepted by the Center for Drug Evaluation (CDE) – confirming its safety and efficacy.

● Low Adverse Reaction Profile: The most common side effect is mild local pain or redness, which typically resolves spontaneously within 1‑3 days without medical intervention. Serious adverse events are extremely rare, further attesting to the vaccine’s excellent safety record.

To conclude, every batch of the Rabies Vaccine After Cat Bite And Scratch Injuries is produced under strict quality management systems, ensuring that healthcare providers and patients receive a product they can trust for life‑critical protection.

Global Supply and Trust

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. has built a robust global supply chain to ensure timely delivery of the Rabies Vaccine  to customers worldwide. Our manufacturing capacity and logistical expertise enable us to meet both routine and urgent demands.

● Extensive Domestic Coverage: Our vaccines are sold across all 31 provinces, cities, and autonomous regions in China, serving over 2,800 district and county CDCs. This nationwide presence reflects the high level of trust placed in our products by Chinese healthcare authorities.

● Growing Export Markets: We have successfully exported to South America, Central Asia, South Asia, and Africa. Key markets include Southeast Asia (20% of exports), Africa (20%), West Asia (20%), South Asia (15%), Central Asia (15%), and South America (10%). We have also initiated cooperation with governments in Pakistan, Kenya, and Egypt.

● International Exhibitions and Partnerships: We regularly participate in global pharmaceutical events such as CPHI Shanghai and CPHI Europe, showcasing our vaccine portfolio and establishing long‑term relationships with international distributors and public health organizations.

● Commitment to Service: Upon receiving your inquiry, our dedicated marketing manager will respond promptly. Once an order is confirmed, the factory reserves the intended batch for you, and shipment is arranged immediately after payment. We support flexible packaging, cold‑chain transportation (2‑8°C), and provide complete documentation for customs clearance.

In short, choosing AIM as your supplier means gaining a reliable partner who understands the urgency of rabies prevention and is equipped to deliver high‑quality vaccines wherever they are needed most.

Frequently Asked Questions

Q: Can I get vaccinated more than 24 hours after a cat bite?

A: Absolutely. While earlier vaccination is better, there is no upper time limit as long as symptoms have not appeared. For severe (Category III) exposure, rabies immunoglobulin must also be given. Do not skip vaccination even if time has passed – it is still effective.

Q: What should I do if I experience redness or low‑grade fever after vaccination?

A: These are common local or systemic reactions, occurring in about 10‑20% of recipients. They usually resolve on their own within 1‑2 days without special treatment. However, if high fever or signs of allergy develop, seek medical attention immediately.

Q: Is the vaccine safe for pregnant or breastfeeding women?

A: Yes. Rabies vaccines (inactivated or genetically engineered) pose no known risk to the fetus or infant. In case of exposure, vaccination should never be withheld – the benefit far outweighs any theoretical risk.

Q: Can rabies still develop after completing the full vaccination course?

A: It is extremely rare. With proper wound care, timely vaccination, and (when indicated) rabies immunoglobulin, the protection rate exceeds 99%. Failures are almost always due to delayed initiation, severe exposure without immunoglobulin, or immunosuppression.

Q: If my pet cat is vaccinated, do I still need vaccination if scratched?

A: Yes, you should still follow the post‑exposure protocol. Animal vaccines are not 100% protective, and the animal’s vaccination status does not eliminate the possibility of virus carriage. Always treat any cat scratch or bite as a potential rabies exposure.

Q: What is the typical delivery time for bulk orders?

A: Usually 30 working days after receipt of payment, though this may vary based on order quantity and specific shipping requirements. We will confirm the exact timeline upon order placement.

Q: How are vaccines transported to ensure quality?

A: All shipments are transported under strict cold‑chain conditions, maintaining temperatures between 2°C and 8°C throughout transit. We provide temperature monitors and full documentation to guarantee vaccine integrity upon arrival.

Q: Do you provide sample vials for testing?

A: Yes, we can provide a limited number of sample vials for evaluation. Please note that samples are typically available for domestic China delivery under ambient conditions; for international samples, we recommend discussing shipping arrangements with our sales team.

Why Choose AIM Honor

The Rabies Vaccine After Cat Bite And Scratch Injuries is a product of AIM Honor’s unwavering commitment to quality, innovation, and global health. With decades of expertise, state‑of‑the‑art facilities, and a customer‑centric approach, we stand ready to support your rabies prevention needs.

● Unmatched Experience: As a leading China manufacturer, we have produced over 100 million doses of rabies vaccines, accumulating extensive real‑world data and continuous improvement in our manufacturing processes.

● Rigorous Quality Control: Our vaccines undergo more than 100 quality tests during production, from raw material screening to final batch release. We adhere to the highest international standards, including WHO prequalification requirements.

● Responsive Customer Support: From initial inquiry to after‑sales service, our professional team ensures a smooth and transparent procurement process. We offer technical documentation, regulatory support, and training materials to assist your healthcare professionals.

● Competitive Advantages: We combine large‑scale production capacity with cost‑efficiency, delivering premium vaccines at competitive prices. Our flexible customization options (packaging, labeling) cater to diverse market requirements.

In conclusion, partnering with AIM Honor means securing a reliable, high‑quality supply of the Rabies Vaccine After Cat Bite And Scratch Injuries – a decision that safeguards lives and reinforces public health efforts against rabies worldwide. Contact us today to discuss your specific needs and let us build a lasting cooperation for a safer tomorrow.